The tumour-targeting human L19-IL2 immunocytokine: Preclinical safety studies, phase I clinical trial in patients with solid tumours and expansion into patients with advanced renal cell carcinomaManfred Johannsen, Filippo de Braud, Hartwig Kosmehl et al.|European Journal of Cancer|2010Cited by 187
Metabolic profiling reveals key metabolic features of renal cell carcinomaGareth Catchpole, Steffen Weikert, Alexander Platzer et al.|Journal of Cellular and Molecular Medicine|2009Cited by 118
Sequence Therapy in Patients with Metastatic Renal Cell Carcinoma: Comparison of Common Targeted Treatment Options Following Failure of Receptor Tyrosine Kinase InhibitorsJonas Busch, Steffen Weikert, Christoph Seidel et al.|European Urology|2011Cited by 45
Efficacy of Sunitinib Re-Exposure after Failure of an mTOR Inhibitor in Patients with Metastatic RCCViktor Grünwald, Manfred Johannsen, Steffen Weikert et al.|Onkologie|2011Cited by 42
Down-regulation of the pro-apoptotic XIAP associated factor-1 (XAF1) during progression of clear-cell renal cancerCarsten Kempkensteffen, Glen Kristiansen, Florian Fritzsche et al.|BMC Cancer|2009Cited by 22